Sacituzumab govitecan: an antibody-drug conjugate
Sheena Sahota1, Linda T Vahdat1
1a Department of Medicine , Weill Cornell Medicine , New York , NY , USA.
Introduction:
Despite advances in the diagnosis and treatment of patients with cancer, patients with metastatic cancer have limited therapeutic options after initial lines of therapy. Understanding tumor biology has translated into the identification of actionable targets that resulted in therapeutics. Antibody-drug conjugates (ADC) are capitalizing on this explosion of scientific information. ADCs allow an antibody to a unique target to be conjugated via an innovative linker, to a highly toxic drug which is delivered to its target. Sacituzumab govitecan is an ADC that combines the active molecule in irinotecan, SN-38, to an antibody targeting trop2. Areas covered: In this review, the authors introduce the reader to the ADC sacituzumab govitecan providing the reader with details about its pharmacokinetics, pharmacodynamics, efficacy and safety. The authors also give their expert analysis about its potential future use. Expert opinion: Sacituzumab govitecan is a novel and well-tolerated therapeutic showing promising results in difficult to treat cancers. Further studies are underway to optimize the group of patients that would benefit from it. Given its excellent performance, we are cautiously optimistic it will be approved by the FDA.
Insights
Sacituzumab govitecan, an antibody-drug conjugate (ADC), shows promise for treating metastatic cancers. This novel therapy targets Trop-2 and delivers SN-38, offering new hope for patients with limited options.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Metastatic cancer patients often have limited treatment options after initial therapies.
- Advances in tumor biology have identified actionable targets for novel therapeutics.
- Antibody-drug conjugates (ADCs) represent a significant advancement in targeted cancer therapy.
Purpose of the Study:
- To review the antibody-drug conjugate sacituzumab govitecan.
- To detail its pharmacokinetics, pharmacodynamics, efficacy, and safety.
- To provide expert analysis on its potential future applications in oncology.
Main Methods:
- Review of existing literature and clinical data on sacituzumab govitecan.
- Analysis of its mechanism of action as an ADC targeting Trop-2.
- Evaluation of pharmacokinetic and pharmacodynamic properties.
Main Results:
- Sacituzumab govitecan demonstrates promising efficacy in difficult-to-treat cancers.
- The drug is generally well-tolerated, with a favorable safety profile.
- Pharmacokinetic and pharmacodynamic data support its targeted delivery mechanism.
Conclusions:
- Sacituzumab govitecan is a novel and effective therapeutic for advanced cancers.
- Further studies are ongoing to refine patient selection for optimal benefit.
- The drug shows potential for FDA approval based on its performance.
More Related Videos
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Related Concept Videos
01:19Mechanism of Conjugation
01:19Conjugation
02:50Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
02:50Conjugated Proteins
01:10Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
02:29Relative Strengths of Conjugate Acid-Base Pairs